Inactivated herpes simplex virus type 2 (HSV-2) (2) and DNA from HSV-2 (6, 20) have been used successfully for the oncogenic transformation of cells in vitro. Recent studies, using specific restriction endonuclease-generated fragments of the HSV-2 genome, have identified two different regions of HSV-2 DNA that can transform cells in vitro (4, 7, 16) . One region, referred to as BglII-N, is contained within the genome map coordinates 0.58 and 0.63 (1) . Cells transformed by BglII-N form colonies in soft agar (16) , contain viral DNA (16) , and form tumors when injected into animals (4) . Support for the association of this fragment with viral transformation has been provided by studies which used 32P-labeled HSV-2 DNA fragments to demonstrate that the BglII N fragment was present in hamster cell lines transformed by inactivated HSV-2 (3) . In view of this association between BglII-N and oncogenic transformation and because polypeptides specified by this fragment have not been identified, we examined the BglII N fragment for encoded products.
We made use of a hybrid plasmid containing the B&III N fragment of HSV-2 DNA to assist in the identification of polypeptides encoded by this DNA segment. This plasmid was used in conjunction with hybrid-arrested translation (12) , mRNA selection (17) , and immunoprecipitation (8) ; our results demonstrate that the major translated product from this DNA fragment has an approximate molecular weight of 37,800 and exhibits HSV-2 immunological specificity.
MATERIALS AND METHODS Cells and virus. HSV-1 strain 17 and HSV-2 strain HG52 were grown and titrated in BHK-21 clone 13 cells (10) .
RNA extraction. Total cytoplasmic RNA was extracted from BS-C-1 cells 6 h after infection as described previously (14) .
Radiolabeling of infected cell polypeptides. Infected or control cell monolayers were washed with phosphate-buffered saline and pulse-labeled with phosphate-buffered saline containing 500 ,uCi -of [35S]methionine (Radiochemical Centre, Amersham, England) per ml. Cells were harvested and prepared for electrophoresis as described previously (11, 14) .
Plasmid DNA. The four hybrid plasmids used in this study were constructed and identified by A. Davidson and I. Cameron (Medical Research Council Virology Unit, Glasgow, Scotland). Plasmid pGZ59 contains HSV-2 BglII-N inserted into the BamHI site of pAT153 (19) . pGZ26 contains HSV-2 HindIII-A cloned in pAT153, and pGZ62 was prepared by cleavage of pGZ26 with BglII, followed by ligation of the fragment consisting of pAT153 plus the regions of BglII-C and BglII-H contained within HindIII-A. Plasmid pGZ15 contains HSV-2 HindIII-H cloned in pAT153. The HindIII and BglII maps of HSV-2 DNA are shown in Fig. 1 , and the structures of plasmids pGZ26, pGZ59 and pGZ62 are illustrated in Fig. 4 .
Isolation of DNA fragments generated by restriction endonuclease cleavage of pGZ59 was performed as described by Preston and McGeoch (15) . 7.4 . A 14-pl amount of cytoplasmic RNA (4 mg/ml), followed by 16 pl of 5 M NaCl, was added, and the reaction mixture was incubated at 580C for 1 h. Polyadenylated RNA was selected on a small ohgodeoxythymidylic acid cellulose column after the addition of 1 ml of HSB (500 mM KCI; 20 mM Trishydrochloride, pH 7.5; 1 mM EDTA). Polyadenylated RNA was ethanol precipitated with 16 ,ug of Escherichia coli rRNA, dissolved in deionized water, and used for in vitro translation either directly or after denaturation by heating at 950C for 1.5 min. mRNA selection. Hybrid plasmid DNA (100,ug) was immobilized on nitrocellulose filters (Schleicher & Scheull Co.) and used for mRNA selection as described by Ricciardi et al. (17) , modified for HSV mRNA by Preston and McGeoch (15) . Hybridizationselected mRNA fractions were purified by oligodeoxythymidylic acid cellulose chromatography before translation in vitro.
In vitro protein synthesis. Samples of RNA were translated in a micrococcal nuclease-treated fractionated reticulocyte cell-free system (13, 14) .
Polyacrylamide gel electrophoresis. Protein samples were resolved on sodium dodecyl sulfate-6 to 15% polyacrylamide gradient gels (11) . Radiolabeled proteins were either visualized by autoradiography on Kodirex film or processed for fluorography (9) and exposed to Kodak XH1 film.
Rabbit sera. Immune sera were prepared by injecting New Zealand white rabbits with primary rabbit kidney cells infected with HSV-1 or HSV-2 and emulsified in Freund complete adjuvant. The animals were test bled periodically and boosted before exsanguination.
Preimmune serum was obtained from each animal before immunization.
Immunoprecipitation. The Staphylococcus aureus Cowan I strain (SPA) was used as an immunoadsorbent to isolate antigen-antibody complexes of radiolabeled viral proteins and rabbit anti-HSV-1 or anti-HSV-2 sera (5, 8) . The immune complexes were dissociated in solubilization buffer, and radiolabeled viral proteins were resolved by gradient polyacrylamide gel electrophoresis and visualized by fluorography (5).
Polypeptide nomenclature. Polypeptides synthesized in vitro and in vivo are classified according to their apparent weights in thousands and prefixed with "VI" or "Vmw," respectively.
Biological containment. All manipulations with bacteria containing plasmids with HSV-2 inserts were performed in a category II laboratory as recommended by the Genetic Manipulation Advisory Group. RESULTS HSV-2-induced polypeptides synthesized in vitro. The RNA preparation used for the experiments described here was extracted from BS-C-1 cells infected with HSV-2 strain HG52.
Characteristic electrophoretic mobilities of HSV-2-induced polypeptides synthesized in vitro have been described previously (14) , but those experiments used RNA from BHK-21-infected cells and were performed without the use of micrococcal nuclease to reduce endogenous protein synthesis in the reticulocyte cell-free system. Therefore, in initial studies polypeptides synthesized in vivo in BS-C-1 cells were compared with translation products of HSV-2-infected BS-C-1 cell RNA (Fig. 2) .
A comparison of polypeptides synthesized by mock-infected and HSV-2-infected BS-C-1 cells showed the presence of 11 major virus-induced polypeptides which corresponded to species described previously (11) . Eleven virus-induced polypeptides were also detected in in vitro translation products, seven of which comigrated with infected cell species synthesized in vivo (Fig. 2 ).
The remaining four (VI 108, VI 78, VI 64, and VI 48) presumably represented precursors which were post-translationally modified in infected cells but not in the reticulocyte cell-free system. Identification of polypeptides encoded by HSV-2 BgM-N. The specificity of mRNA's homologous to the BglII N fragment was determined by hybrid-arrested translation or mRNA selection with pGZ59 (Fig. 3) . The first of these techniques relies on the inability of duplexed mRNA to be translated in vitro after hybridiza- (11, 14) . tion to plasmid DNA. Two important controls for this technique are demonstration of recovery of mRNA activity upon denaturation of hybrids (14) and the use of unrelated DNA, or no DNA, since some HSV mRNA's are inactivated by mock hybridization (15) .
Translation of RNA after hybridization to pGZ59 resulted in a reduction or inhibition of synthesis of polypeptides VI 41.5 and VI 37. 8 ( Fig. 3, lane 4) . Their activities returned after denaturation of hybrids (Fig. 3, lane 5) ; therefore, these are candidates for BglII-N-specified polypeptides. When mock hybridization with no DNA was performed, however, synthesis of VI 41.5 was similarly reduced (Fig. 3, lanes 8 and  9) , although no effect on VI 37.8 was noted. This suggests that the arrest of VI 41.5 synthesis was not due to BglII-N sequences. Plasmid pGZ15, which contains the HSV-2 HindIII H fragment (0.29 to 0.40 map unit), was used as a further control. The expected inhibition of synthesis of polypeptides VI 42.5 and VI 41.5, which has previously been mapped in this region (11), occurred (Fig. 3, lanes 6 and 7) , but again no effect on VI 37.8 was observed.
Translation of BglII-N-specific RNAs selected by hybridization to nitrocellulose filters loaded with pGZ59 DNA is shown in Fig. 3 , lane 3. The major product, apart from two endogenous reticulocyte bands (approximate molecular weights, 49,000 and 110,000), had an apparent molecular weight of about 37,800. Another minor BgIII-N-specified band had an apparent molecular weight of 15,000, although size estimates in this region of the gel are unreliable due to overloading with globin (Fig. 3, lane 3) . These two polypeptides were not observed when control pAT153 DNA-containing filters were used for mRNA selection (data not shown).
Therefore, the two mapping techniques, in Hybrid-arrested translation and mRNA selection studies, using HSV-2 mRNA with pGZ59 DNA orpGZ15 DNA. The fluorogram shows proteins synthesized in vitro, using a fractionated reticulocyte system with the following additions: (1) mock-infected cell RNA; (2) HSV-2-infected cell RNA; (3) pGZ59-selected HSV-2 mRNA; (4) HSV-2 mRNA hybridized with pGZ59 DNA; (5) as (4) but denatured before translation; (6) HSV-2 mRNA hybridized with pGZ15 DNA; (7) as (6) but denatured before translation; (8) HSV-2 mRNA under hybridization conditions but no DNA present; (9) as (8) but denatured before translation; (10) as (2); (11) endogenous products of the translation system after the addition ofE. coli rRNA. Numbers in the left margin are apparent molecular weights x 10-3. which different hybridization conditions are used, agree that the major mRNA homologous to BglII-N, in the cytoplasmic RNA preparation used, encoded a polypeptide which comigrates with Vmw 37.8 found in infected cells.
A more precise location of coding sequences for VI 37.8 was determined with restriction endonuclease fragments of pGZ59 and clone pGZ62, which contains sequences adjacent to BglII-N, in hybrid-arrested translation (Fig. 4) .
Cleavage of pGZ59 with restriction enzyme HindIII plus BamHI generated three bands upon electrophoresis. The largest of these contained pAT153 sequences plus BglII-N sequences representing 0.61 to 0.63 map unit on the HSV-2 genome (Fig. 4, solid lines) . The smaller bands collectively contained BglII-Nderived sequences from 0.58 to 0.61 HSV-2 map unit plus a part of pAT153 (Fig. 4, broken lines) . Hybrid-arrested translation revealed that the combined lower two bands arrested the synthesis of VI 37.8, whereas the upper band did not (Fig. 4, lanes 8 to 11) . Plasmid pGZ62, containing the portion of BglII-C adjacent to BgIII-N (approximately 0.53 to 0.58 map unit), failed to prevent the synthesis of VI 37.8 in hybrid-arrested translation (Fig. 4, lanes 6 and 7) . Se (Fig. 5, lane 4) and also cross-reacted with many of the HSV-1 polypepties synthesized in vitro (Fig. 5, lane 6 ). This serum did not, however, precipitate any of the polypeptides synthesized with RNA from mock-infected cells (Fig. 5, lane  7) . When the anti-HSV-2 serum was reacted with products of pGZ59-selected RNA, VI 37.8 was the only polypeptide detectably precipitated (Fig. 5, lane 5) . Preimmune serum did not precipitate VI 37.8 synthesized from pGZ59-selected or total cytoplasmic RNA (data not shown).
Although the above studies suggested that the polypeptide was virus specific, they did not indicate whether VI 37.8 shared cross-reacting antigenic determinants between HSV-1 and HSV-2. Therefore, viral proteins were synthesized in vitro from pGZ59-selected mRNA and cytoplasmic RNA from HSV-1-or HSV-2-infected cells. These proteins were incubated with anti-HSV-1 or anti-HSV-2 serum, and the reaction was monitored by the SPA-polyacrylamide gel electrophoresis-fluorography system as described above. When anti-HSV-2 serum was reacted with VI 37.8 synthesized from pGZ59-selected mRNA, the result was a positive precipitation (Fig. 6, lane 5) . When this polypeptide was reacted with rabbit anti-HSV-1 serum, no precipitation was observed (Fig. 6, lane 4) . These studies were continued with proteins synthesized in vitro from total HSV-1 or HSV-2 cytoplasmic mRNA as antigens. When these preparations were reacted with their homologous antibodies, most of the polypeptides were precipitated efficiently (Fig. 6, lanes 2 and 6) . When HSV-1 antigens were reacted with HSV-2 antibody or HSV-2 antigens were reacted with HSV-1 antibody, extensive cross-reactivity was observed with many of the antigens precipitated by heterologous serum (Fig. 6, lanes 3 and 7) . The most notable difference in these results was that anti-HSV-1 serum did not precipitate the 37,800-dalton polypeptide (Fig. 6, lane 3) , which is consistent with the lack of precipitation seen when this antiserum was reacted with pGZ59-selected mRNA products (Fig. 6, lane 4) . However, the 37,800-dalton polypeptide, plus others, was effectively precipitated by anti-HSV-2 serum (Fig.  6, lane 6) . Proteins synthesized from cytoplasmic RNA of mock-infected cells were not precipitated by either anti-HSV-1 or anti-HSV-2 sera (Fig. 6, lanes 9 and 10) . These studies were repeated with anti-HSV-1 sera from two additional rabbits and anti-HSV-2 sera from two additional rabbits with the same results. DISCUSSION In this study, the BgM N fragment of HSV-2 DNA was examined for encoded polypeptides by using the techniques of hybrid-arrested translation and mRNA selection. Our results demonstrated that the information for one polypeptide, VI 37.8, is contained within this DNA fragment and under our experimental conditions represented the major translatable mRNA from this region of the genome. A second polypeptide, VI 15, was observed in mRNA selection studies base pairs of the thymidine kinase mRNA. Plasmid pGZ62 fails to arrest the synthesis of VI 37.8 or select its mRNA under a variety of hybridization conditions (data not shown); therefore, it is probable that all coding sequences for VI 37.8 lie within BglII-N, although some untranslated regions may extend into the adjacent BglII C fragment. Analysis of the structure of VI 37.8 mRNA will be necessary to test this possibility.
The assignment of VI 37.8 to approximately 0.58 to 0.61 map unit on the HSV-2 genome appears to conflict with the map position of 0.44 to 0.57 obtained from an analysis of HSV-1 x HSV-2 intertypic recombinants (11) . A re-examination of those data reveals that although recombinant B x 1 (24) clearly failed to induce Vmw 37. 8 Mapping studies to position VI 37.8 suggest that the coding sequences for the polypeptide lie entirely within the BglII N fragment of HSV-2 DNA. The limits of these experiments can be assessed, to some extent, by reference to previous studies designed to map the thymidine kinase mRNA encoded by the HSV-1 BamHI P fragment (15) . In this case, it was found that efficient arrest of translation can be achieved by fragments which overlap the coding sequences at the 3' terminus by only 20 base pairs. Fragments which hybridize to the 5' untranslated region also arrest translation, although a modification of the reaction conditions is necessary. HSV-I proteins synthesized in vitro plus anti-HSV-I serum; (3) HSV-2 proteins-synthesized in vitro plus anti-HSV-I serum; (4) VI 37.8 synthesized in vitro from pGZ59-selected mRNA plus anti-HSV-I serum; (5) as (4) but anti-HSV-2 serum; (6) as (3) but anti-HSV-2 serum; (7) as (2) but anti-HSV-2 serum; (8) HSV-2-infected cell proteins synthesized in vitro; (9) mock-infected BS-C-I cell proteins synthesized in vitro plus anti-HSV-I serum; (10) as (9) but anti-HSV-that two HSV-2 polypeptides with molecular weights of 38,000 and 118,000 were immunoprecipitated more frequently by sera from uterine cervical cancer patients than by sera from control patients (5) . Both polypeptides appeared to be HSV-2 specific, and their immunological reactivity was correlated with the presence of HSV-2-specific antibodies in patient sera and a variety of social and economic factors. In the present study, the VI 37.8 polypeptide was similar in molecular weight and immunological specificity to one of these tumor-associated proteins. Additionally, when Suh et al. (18) performed immunoprecipitation studies with proteins from HSV-2-transformed hamster cells, 11 polypeptides were precipitated by anti-HSV-2 sera. Notably, three of these polypeptides have molecular weights of 38,000, 37,500, and 35,000, which are similar in molecular weight to VI 37. 8 .
The finding that VI 37.8 is a major product encoded by the BglII-N region of HSV-2 DNA and that it has a molecular weight similar to that of a viral polypeptide found in HSV-2-transformed hamster cells (18) and may be precipitated by human sera from cervical cancer patients (5) is of considerable interest to HSV-2 oncogenesis. This study does not, however, establish the tumor relatedness of this polypeptide or whether it has a functional role in cell transformation. This could be investigated further by examining the transforming ability of pGZ59 after cleavage with various restriction enzymes or mutagenesis in vitro, since we have shown that VI 37.8 lies within the region of 0.58 to 0.61 map unit on the HSV-2 genome. The experiments reported here also provide a basis for studying HSV-2 gene expression in BglII-Ntransformed cells, since at least one gene product encoded by this DNA fragment is now known.
